< Return to Video

Changing the future with stem cells | Crystal Ruff | TEDxLondonBusinessSchool

  • 0:12 - 0:14
    For the past 12 years,
  • 0:14 - 0:19
    I have been a researcher
    in the field of regenerative medicine.
  • 0:19 - 0:21
    As a doctor of neuroscience,
  • 0:21 - 0:24
    my work investigates
    whether or not we can use stem cells
  • 0:24 - 0:28
    to help children who have had brain injury
    or adults with spinal cord injury.
  • 0:30 - 0:32
    Today, I am going to speak with you
  • 0:32 - 0:36
    about how we are changing
    the future with stem cells.
  • 0:37 - 0:42
    I believe that stem cells
    are the new Internet.
  • 0:43 - 0:45
    Think about it.
  • 0:45 - 0:52
    Think about how the Internet completely
    changed the way that we communicate,
  • 0:52 - 0:54
    the way that we do business,
  • 0:54 - 0:58
    and even the way
    that we gather data and information.
  • 0:58 - 1:05
    Similarly, I believe that stem cells
    have the power to revolutionize
  • 1:05 - 1:08
    the whole concept of healthcare.
  • 1:09 - 1:12
    So to start, let's have
    a little audience participation.
  • 1:12 - 1:16
    Put your hand up: how many of you
    have heard of the term "stem cells"?
  • 1:16 - 1:20
    Now leave your hand up
    if you can tell me what they are.
  • 1:22 - 1:27
    This illustrates a very important part
    of my work in science communications.
  • 1:27 - 1:30
    Most of us have heard
    of the term stem cells
  • 1:30 - 1:33
    either through the media
    or through our friends,
  • 1:33 - 1:36
    but very few of us
    actually know what they are,
  • 1:36 - 1:40
    what they can do,
    and, importantly, what they can't do.
  • 1:40 - 1:44
    So, today, we're going to speak
    a little about what stem cells are,
  • 1:44 - 1:46
    we're going to look
    at what they're currently being used for,
  • 1:46 - 1:49
    and where the future of the field lies.
  • 1:50 - 1:55
    So, you can't be expected to understand
    about stem cell treatments
  • 1:55 - 1:58
    if you don't understand
    what stem cells are to begin with.
  • 1:58 - 2:01
    This is something
    that I like to call "Stem Cells: 101".
  • 2:02 - 2:05
    We all know that the hundreds of cells
    in the human body
  • 2:05 - 2:08
    all originate from one fertilized egg.
  • 2:08 - 2:12
    If you think of this
    as a ball rolling down a hill:
  • 2:12 - 2:17
    at the top of the hill, the ball can go
    to any number of destinations downhill,
  • 2:17 - 2:21
    but as it rolls down guided by gravity,
    it hits a series of forks in the road.
  • 2:21 - 2:25
    After which it must make a decision
    to go one way or the other,
  • 2:25 - 2:29
    and that restricts its potential outcomes.
  • 2:30 - 2:34
    Similarly, stem cells
    during the process of differentiation
  • 2:34 - 2:36
    face a series of fate decisions
  • 2:36 - 2:40
    where they must choose
    which cell type to specialize into,
  • 2:40 - 2:42
    and they cannot go back.
  • 2:43 - 2:46
    Near the top of the hill,
    you see pluripotent stem cells:
  • 2:46 - 2:49
    "pluri-" meaning "many";
    "potent", "potencies".
  • 2:50 - 2:53
    Embryonic pluripotent stem cells
  • 2:53 - 2:57
    are the type of stem cell that people
    most often associate with the word.
  • 2:57 - 3:03
    However, in reality, these cells
    are virtually never used
  • 3:03 - 3:04
    in transplant paradigms.
  • 3:04 - 3:09
    Instead, we differentiate the cell down
    into multipotent progenitors
  • 3:09 - 3:12
    that are very specialized for the type
    of tissue that we want to get.
  • 3:13 - 3:17
    It's important to note
    that one type of multipotent cell
  • 3:17 - 3:19
    cannot make adult cells of another type.
  • 3:19 - 3:24
    For example, fat stem cells
    cannot make cells of the brain or the eye,
  • 3:24 - 3:26
    and vice versa.
  • 3:27 - 3:29
    So, you might ask,
  • 3:29 - 3:33
    if pluripotent stem cells can turn
    into any cell in the body,
  • 3:33 - 3:35
    why don't we just inject those?
  • 3:35 - 3:37
    You know, they could go to the site,
  • 3:37 - 3:40
    they could travel to the site
    of whatever is injured
  • 3:40 - 3:42
    and turn into the cells that we need.
  • 3:43 - 3:44
    Right?
  • 3:44 - 3:45
    Wrong!
  • 3:45 - 3:47
    Because they could turn
    into something like this.
  • 3:47 - 3:50
    This is called a teratoma.
  • 3:50 - 3:53
    The problem is once we put stem cells in,
  • 3:53 - 3:57
    we cannot control where they go
    or what cells they turn into.
  • 3:57 - 4:00
    They could turn
    into all of the cells in the body
  • 4:00 - 4:03
    all at once, all in the same place.
  • 4:03 - 4:09
    Here you can see hair,
    fat, tooth, gut, bone -
  • 4:10 - 4:14
    imagine if this were
    in your brain or your eye.
  • 4:15 - 4:17
    This is why we must differentiate cells
  • 4:17 - 4:20
    into the specific progenitors
    as much as possible
  • 4:20 - 4:22
    before we're thinking
    of transplanting them in.
  • 4:23 - 4:29
    Now, all of our adult tissue has
    its own multipotent cells within it,
  • 4:29 - 4:34
    that's what helps us to grow
    or when we're repairing injury,
  • 4:34 - 4:36
    and these can be harvested
    in many tissues,
  • 4:36 - 4:40
    and grown in the lab
    for transplanting paradigms.
  • 4:40 - 4:44
    However, there are some tissues
    that you can't harvest.
  • 4:45 - 4:47
    Think about the brain
    or the heart or the eye.
  • 4:47 - 4:50
    Going in there to get cells
    could kill you.
  • 4:50 - 4:55
    So we have to think of other alternative
    cell sources for these cells.
  • 4:55 - 4:58
    And this is where
    pluripotent cells come in.
  • 4:58 - 5:03
    Now, up until now, embryonic drive cells
    have been differentiated down the hill
  • 5:03 - 5:07
    into the stem cell types that we need.
  • 5:08 - 5:11
    Recently, induced pluripotent
    stem cells were developed
  • 5:11 - 5:15
    where you can take adult skin samples,
    your own consenting adult,
  • 5:15 - 5:18
    push them back up the hill
    using four chemical factors,
  • 5:18 - 5:21
    and then differentiate them down
    to the cell type you need.
  • 5:21 - 5:24
    This was discovered recently
    by Shinya Yamanaka,
  • 5:24 - 5:26
    who went on to win the Nobel Prize.
  • 5:26 - 5:30
    The good thing about this is
    it uses non embryonic sources,
  • 5:30 - 5:33
    and it's your own tissue,
    so your body is not likely to reject it.
  • 5:33 - 5:39
    Alternatively, direct lineage
    reprogramming - there we go -
  • 5:39 - 5:41
    takes you from A to B
  • 5:41 - 5:43
    without this intermediate
    step up the hill.
  • 5:43 - 5:46
    You can take adult skin samples
  • 5:46 - 5:49
    and differentiate them directly
    into the cell type you choose
  • 5:49 - 5:51
    using different chemical triggers.
  • 5:51 - 5:55
    Now, this is only
    in the lab phases, it's very new,
  • 5:55 - 5:57
    but it represents
    a very interesting direction
  • 5:57 - 5:59
    into where the field is heading.
  • 6:01 - 6:04
    So, what we are we doing with stem cells?
  • 6:04 - 6:06
    Here's another audience participation.
  • 6:06 - 6:11
    How many of you are affected by,
    or know someone who has been affected by,
  • 6:11 - 6:12
    any of these diseases?
  • 6:12 - 6:14
    Put up your hands.
  • 6:14 - 6:17
    Stroke, burns, diabetes,
    injuries to joints.
  • 6:18 - 6:20
    Now look around.
  • 6:21 - 6:27
    Every single one of us
    is affected by diseases
  • 6:27 - 6:31
    that stem cells could potentially
    one day help treat.
  • 6:33 - 6:38
    Just because we are putting stem cells
    into the first person in the first trial
  • 6:38 - 6:40
    doesn't mean these are a treatment,
  • 6:40 - 6:43
    doesn't mean it's
    a regular accepted treatment.
  • 6:43 - 6:44
    As you can see here,
  • 6:44 - 6:47
    it can take up to ten years or over
  • 6:47 - 6:50
    to get through
    the clinical trials pipeline.
  • 6:50 - 6:52
    Science is incremental,
  • 6:53 - 6:56
    but the good news is
    we have a lot of treatments
  • 6:56 - 6:59
    that have been in the pipeline
    for many years,
  • 6:59 - 7:01
    that are just now starting to come out.
  • 7:02 - 7:05
    Furthermore, now more than ever before,
  • 7:05 - 7:10
    scientists, clinicians,
    members of the public, policymakers,
  • 7:10 - 7:15
    are all working together
    to streamline this process.
  • 7:15 - 7:18
    That means we can get
    the best stem cell treatments out
  • 7:18 - 7:22
    to the people who need them the most
    in the shortest amount of time.
  • 7:22 - 7:25
    So here you see these diseases
    are colour-coded
  • 7:25 - 7:27
    based on where they are on the pipeline.
  • 7:27 - 7:30
    You can see that we have
    two current treatments using stem cells
  • 7:30 - 7:32
    here in green.
  • 7:32 - 7:34
    The first for bone and blood cancer
  • 7:34 - 7:38
    you might know of
    as a bone marrow transplant.
  • 7:38 - 7:40
    Been used for decades.
  • 7:40 - 7:44
    The next stem cell product
    to come out of the pipeline
  • 7:44 - 7:45
    is for burns and wound healing.
  • 7:45 - 7:51
    This uses skin tissue
    and helps with vision burns as well.
  • 7:52 - 7:55
    Today we're going to focus
    on two major areas
  • 7:55 - 7:56
    that we're using stem cells in.
  • 7:56 - 7:58
    The first is stroke.
  • 7:58 - 8:01
    This is my work in childhood brain injury.
  • 8:02 - 8:07
    Did you know that cerebral palsy
    is more common
  • 8:07 - 8:12
    than juvenile AIDS, childhood leukaemia,
    muscular dystrophy,
  • 8:12 - 8:15
    and juvenile diabetes combined.
  • 8:16 - 8:19
    Cerebral palsy, which means
    problems sending signals
  • 8:19 - 8:22
    from the brain to the muscles
    creating movement
  • 8:22 - 8:26
    is the most common
    neurodevelopmental disability.
  • 8:27 - 8:28
    What my work does,
  • 8:28 - 8:31
    is we inject stem cells into the brain
  • 8:31 - 8:36
    which are able to incorporate
    and turn into the site types of cells
  • 8:36 - 8:38
    that are lost in the most
    common forms of brain injury.
  • 8:38 - 8:41
    They can enhance function
    and restore brain tissue.
  • 8:41 - 8:44
    And what my work in particular
    has been able to show
  • 8:44 - 8:49
    is that we are able to functionally
    double the signal speed
  • 8:49 - 8:51
    in the brains of animals.
  • 8:51 - 8:54
    What could this mean for a child
    with cerebral palsy?
  • 8:54 - 8:57
    This could mean the potential
    for normal movement,
  • 8:57 - 9:01
    the ability to go out and run and jump,
    to play with their friends.
  • 9:01 - 9:03
    Very exciting stuff.
  • 9:03 - 9:08
    Right now, these cells are being used
    in clinical trials only.
  • 9:08 - 9:11
    There are trials in adults
    looking at stroke,
  • 9:11 - 9:14
    and there are adult trials
    looking in spinal cord injury.
  • 9:15 - 9:18
    The same cells are lost in these models.
  • 9:18 - 9:22
    Importantly, the first clinical trial
    using these types of cells
  • 9:22 - 9:24
    has now started in children.
  • 9:27 - 9:31
    Next, I want to focus
    on a very interesting area
  • 9:31 - 9:35
    that's combining 3D bioprinting
    with stem cell regenerative medicine.
  • 9:35 - 9:38
    This is in red, because it is
    only in the early stages,
  • 9:38 - 9:41
    but I think it represents
    a very exciting avenue
  • 9:41 - 9:43
    through which the field is heading.
  • 9:44 - 9:47
    With improvements
    in imaging software and technology,
  • 9:47 - 9:52
    we are now able to make accurate 3D images
  • 9:52 - 9:55
    and take scans of body structures
    inside the body.
  • 9:56 - 9:59
    Using AutoCAD and 3D software,
  • 9:59 - 10:05
    we are able to make CAD designs
    which can be printed using 3D bioprinters.
  • 10:05 - 10:08
    These bioprinters are kind of like
    the printers you have at home,
  • 10:09 - 10:12
    only, instead of using ink,
    they use special biogels
  • 10:12 - 10:15
    to create the structures
    that you have in the body.
  • 10:16 - 10:20
    After that, you can seed them
    with stem cells.
  • 10:20 - 10:23
    Here you see a heart valve being printed
  • 10:23 - 10:26
    which can then later be seeded,
    possibly with your own stem cells.
  • 10:27 - 10:30
    There's an image on the inset
    of the heart valve.
  • 10:30 - 10:34
    There's also an image of an ear
    being seeded with stem cells
  • 10:34 - 10:35
    which can be your own.
  • 10:35 - 10:38
    Underneath, you see
    a 3D printed image of a trachea.
  • 10:38 - 10:43
    On the bottom right, you see an interview
    that I recently did with CTV national news
  • 10:43 - 10:48
    on the youngest ever
    transplant recipient of a trachea
  • 10:48 - 10:49
    seeded with her own stem cells.
  • 10:50 - 10:55
    It's important to note
    that while this is very exciting,
  • 10:55 - 10:57
    it is still in its infancy.
  • 10:57 - 11:00
    We cannot make complicated structures
    with multiple cell types,
  • 11:01 - 11:04
    and right now, it is just very basic.
  • 11:04 - 11:06
    But think about where this can head.
  • 11:07 - 11:11
    Think about whether we could
    use it in the future
  • 11:11 - 11:15
    to print structures in the body
    and use our own cells for transplant.
  • 11:16 - 11:19
    So this is a very exciting field,
  • 11:19 - 11:23
    but as with every potentially
    game-changing technology,
  • 11:23 - 11:25
    there are challenges.
  • 11:25 - 11:29
    This used to centre around the use
    of embryonic drive stem cells,
  • 11:29 - 11:33
    but, recently, with the advent
    of the induced pluripotent stem cells
  • 11:33 - 11:34
    and direct lineage reprogramming,
  • 11:34 - 11:39
    which can use your own adult
    consenting tissues,
  • 11:39 - 11:42
    this conversation has become
    less and less relevant.
  • 11:43 - 11:45
    What we see,
  • 11:45 - 11:50
    especially with the the increase
    of treatments coming out of the pipeline,
  • 11:50 - 11:54
    is misrepresentation
    of stem cell strategies.
  • 11:55 - 12:02
    Here, some doctors are offering
    unproven treatments using stem cells
  • 12:02 - 12:04
    for profit.
  • 12:05 - 12:09
    Unproven - that means
    a) not proven to work,
  • 12:09 - 12:13
    and b) not proven to be safe.
  • 12:14 - 12:17
    Recently, "Scientific American"
    had an article
  • 12:17 - 12:22
    about a woman who went
    to a very fancy clinic in Beverly Hills
  • 12:22 - 12:26
    and got the latest stem cell facelift
    that they were offering.
  • 12:27 - 12:33
    The doctors took advantage
    of a loophole in the law,
  • 12:34 - 12:37
    sucked out her fat,
    and put the stem cells in her face
  • 12:37 - 12:41
    to make her rejuvenated,
    or healthier or something.
  • 12:41 - 12:45
    And while they were under the hood,
    they gave her dermal filler.
  • 12:46 - 12:50
    What the doctors didn't take into account
  • 12:50 - 12:52
    is that dermal filler
  • 12:52 - 12:57
    differentiates fat stem cells
  • 12:57 - 13:00
    into bone.
  • 13:00 - 13:05
    So this woman was left
    with bone fragments in her eyelids.
  • 13:07 - 13:14
    This is why we need clinical trials
    to make sure that treatments are safe.
  • 13:14 - 13:18
    If you were to take a drug,
    and you had a bad side effect,
  • 13:18 - 13:22
    you could stop taking the drug,
    and that side effect would go away.
  • 13:22 - 13:25
    But it's not the case with stem cells.
  • 13:25 - 13:29
    Once stem cells are put in,
    they can never be taken back out.
  • 13:30 - 13:33
    Furthermore, going
    to an unregulated clinic
  • 13:33 - 13:36
    can exclude you
    from future legitimate trials.
  • 13:36 - 13:40
    So, how do you know
    whether or not what you're looking at
  • 13:40 - 13:44
    is a real stem cell treatment
    or misrepresentation?
  • 13:44 - 13:48
    Here are some hints that can help you,
    it's a difficult field to navigate.
  • 13:48 - 13:51
    The first: look at
    how many cell types per injury.
  • 13:51 - 13:57
    We mentioned that cell types need to be
    very specific to replace damaged tissue,
  • 13:57 - 14:01
    and one stem cell type
    cannot turn into cells of another.
  • 14:01 - 14:03
    So it's very important if someone's saying
  • 14:03 - 14:05
    they're going to suck out
    one type of stem cell
  • 14:05 - 14:08
    and use it for 12 different indications,
  • 14:08 - 14:10
    it's likely something you should question.
  • 14:10 - 14:13
    Second of all: you can check out
    their preclinical track record;
  • 14:13 - 14:16
    clinicaltrials. gov
    is a comprehensive database
  • 14:16 - 14:20
    of all of the clinical trials
    if they want to get FDA approval.
  • 14:21 - 14:23
    And the third and most important
    thing that you can do
  • 14:23 - 14:25
    is to be knowledgeable.
  • 14:26 - 14:29
    Do your research and get consensus.
  • 14:30 - 14:35
    Ask your doctors, all of them,
    because they are here to help you.
  • 14:37 - 14:43
    So, overall stem cells have the potential
  • 14:43 - 14:47
    to change life as we know it.
  • 14:48 - 14:53
    Every single one of us
    is affected by diseases
  • 14:53 - 14:57
    which stem cells could potentially
    help to treat in the future.
  • 14:58 - 15:03
    And now that you have the knowledge,
    you have the power.
  • 15:03 - 15:07
    It is up to you to spread
    the word about stem cells
  • 15:07 - 15:09
    and to support reputable clinical trials,
  • 15:10 - 15:13
    so that we can work hard
    to get the best treatments out
  • 15:13 - 15:17
    to the people who need them the most
    in the shortest possible amount of time.
  • 15:18 - 15:23
    Right now, there are
    many - more than ever before - treatments
  • 15:23 - 15:25
    in the pipeline, ready to come out.
  • 15:25 - 15:29
    And the field of regenerative medicine
    is at critical mass.
  • 15:30 - 15:34
    So I ask you to come join me
    on this journey.
  • 15:34 - 15:40
    Come with me as newly-minted purveyors
    of stem cell knowledge
  • 15:41 - 15:45
    as we turn science fiction
    into science fact.
  • 15:45 - 15:46
    Thank you.
  • 15:46 - 15:48
    (Applause)
Title:
Changing the future with stem cells | Crystal Ruff | TEDxLondonBusinessSchool
Description:

This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at http://ted.com/tedx

Every single one of us is affected by diseases which stem cells could potentially treat in the future. Dr Crystal Ruff explains what stem cells are and how they are changing the way we treat diseases.

Crystal is a keen investigator in the field of regenerative neuroscience and translational health research, with a proven track record of academic and performance excellence. She concluded her MBA at the London Business School in July 2016.
Crystal's expertise lies in stem cell therapies and their transition from the lab to the clinic in order to help commercialize these strategies and get the best treatments out to the public. As a postdoctoral fellow in the Fehlings Laboratory for Neural Repair and Regeneration at the University of Toronto in Canada, she spearheaded the stem cell therapy for cerebral palsy animal initiative. Her work in knowledge translation of regenerative medicine involves several internationally-distributed documents, as well as information packages produced for the White House Office of Science & Technology Policy working group and CTV news.

more » « less
Video Language:
English
Team:
closed TED
Project:
TEDxTalks
Duration:
15:59
  • Not sure why Note#2 (Robert's) and Note #3 (mine) aren't visible:

    Thank you, Denise.

    I'll just put in the capital (and not get into a long discussion about punctuation!).

    Regards

    Robert Tucker - 5:05 AM

    Hi Robert,

    Your change at 13:14 from 'if' to 'If' is correct, don't see why should, or if ever, we've gotten into a long discussion about punctuation.

    Best regards and see you around.

    ***

  • All notes visible to me.

    Certainly I can't always schedule whether a Harvard/Oxford comma is necessary at a certain point, or exactly which part(s) of a sentence need(s) splitting off with commas, for priority time!

  • Not sure I can follow, Robert. There was no comment on scheduling on my part...

    ***

    "Not sure why Note#2 (Robert's) and Note #3 (mine) aren't visible" goes to Support Team.

  • Sorry, Denise, I'm simply saying that some punctuation is a matter of personal preference and, unless it's something bothering someone else, not something I tend to stop and consider for too long.

  • Dear Robert, to sum-up:

    In the Amara Editor, during the approval process, I left a first note.
    Note #1 is: "Great transcript, Robert! Please let me know if you have any comments or anything else is needed. Best regards,"

    I noticed this note is visible, both where it was left (Amara's editor), and if you visit Yasushi's tool under 'Notes'.

    ***
    Though I approved the task, you re-edit, and left a note for me. Your note, (note #2), said:

    "Thank you, Denise.

    I'll just put in the capital (and not get into a long discussion about punctuation!).

    Regards".

    This note #2 is only visible in the Amara editor; but not visible in the Yasushi's tool under 'Notes'. Not sure why!

    And from there, much later on, I left a comment for the Support Team in my note #4.

    ***
    To offer an answer to your note though, in the meantime, I I re-accessed the task, and left a note for you. This note, (note #3), is the following, and again(!),it is visible only in the Amara editor, but not under 'notes' in the Y's tool. Not sure why!

    And that's why, much later on, I left note #4 for Support.

    My note, note #3, meant for you, said:

    "Hi Robert,

    Your change at 13:14 from 'if' to 'If' is correct, don't see why should, or if ever, we've gotten into a long discussion about punctuation.

    Best regards and see you around."

    As you can re-check note #3, in my last and second note meant for you, I didn't contest your change from 'if' to 'If' (which was in fact a lowercase to a capital letter, and not a comma issue altogether), I made no other comment for you, and in fact I simply stated that 'you were right' and did an excellent job.

    ***
    Then, much later, noticing the absence of these comments under 'notes', I left another note (note #4 in the Amara editor) and a comment in here, only for the Amara Support Team.

    I hope this clarifies everything, Robert.

    ***
    To alert Support again, I'll leave and comment on my question again: Note #4:

    "Not sure why Note#2 (Robert's) and Note #3 (mine) aren't visible!

    They are:

    Thank you, Denise.

    I'll just put in the capital (and not get into a long discussion about punctuation!).

    Regards

    Robert Tucker - 5:05 AM

    Hi Robert,

    Your change at 13:14 from 'if' to 'If' is correct, don't see why should, or if ever, we've gotten into a long discussion about punctuation.

    Best regards and see you around."

    Can Support offer an answer? Thanks everyone!

    ***

English subtitles

Revisions Compare revisions